Crossmark Global Holdings Inc. Invests $866,000 in Immunocore Holdings plc (NASDAQ:IMCR)

Crossmark Global Holdings Inc. bought a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 27,803 shares of the company's stock, valued at approximately $866,000. Crossmark Global Holdings Inc. owned about 0.06% of Immunocore as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Exchange Traded Concepts LLC lifted its holdings in Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after buying an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC bought a new position in Immunocore during the third quarter worth $218,000. China Universal Asset Management Co. Ltd. boosted its holdings in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after purchasing an additional 3,053 shares during the period. DNB Asset Management AS increased its stake in Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company's stock valued at $244,000 after purchasing an additional 1,868 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Immunocore during the second quarter worth $303,000. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Price Performance

Shares of IMCR stock traded down $0.14 during mid-day trading on Friday, hitting $32.48. 153,281 shares of the stock traded hands, compared to its average volume of 519,173. The company's 50-day simple moving average is $32.48 and its 200-day simple moving average is $38.84. Immunocore Holdings plc has a twelve month low of $29.72 and a twelve month high of $76.98. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -34.00 and a beta of 0.72. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. During the same quarter last year, the firm posted ($0.59) EPS. The business's revenue for the quarter was up 23.7% on a year-over-year basis. As a group, equities research analysts expect that Immunocore Holdings plc will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. UBS Group started coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a "sell" rating and a $24.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Immunocore in a research report on Monday, September 9th. Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $72.00 to $38.00 in a research report on Monday. Barclays reduced their price target on shares of Immunocore from $92.00 to $66.00 and set an "overweight" rating for the company in a report on Friday, August 9th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $69.18.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.